Valeant Pharmaceuticals asked its CEO to cooperate with a Senate investigation into drug pricing after he failed to appear for a deposition. The Senate Special Committee on Aging said last week that it planned to start legal proceedings against J. Michael Pearson, who is leaving Valeant after months of turmoil for the drugmaker. Pearson is still under subpoena to appear before the committee A sign for the headquarters of Valeant Pharmaceuticals International Inc is seen in Laval, Quebec June 14, 2016. REUTERS/Christinne Muschi Purchase Licensing Rights, opens new tab Geoffrey S. Berman, the United States Attorney for the Southern District of New York, announced that GARY TANNER, a former executive at Valeant Pharmaceuticals International, Inc. ("Valeant"), was sentenced today to 1 year and 1 day in prison, and ANDREW DAVENPORT, the former chief executive officer ("CEO") of Philidor Rx Services LLC ("Philidor"), was sentenced today to 1 year and Former Valeant Pharmaceuticals International Inc Chief Executive Michael Pearson has filed a lawsuit against the Canadian drugmaker, alleging it refused to pay him more than 3 million shares he is U.S. feds building accounting fraud case against Valeant, with former CEO, CFO at the center: Report By Carly Helfand Nov 1, 2016 9:18am Philidor Valeant Pharmaceuticals Bausch Health, the Canada-based drugmaker formerly known as Valeant Pharmaceuticals, agreed to pay $45 million to settle U.S. charges that it misled investors by improperly accounting for revenue channeled through a mail-order pharmacy it helped to set up. Michael Pearson, Valeant's once high-flying CEO, and two other former company |vnl| lbd| nxe| aod| aeo| vat| dfw| sru| rvb| wnq| lgc| nyi| uho| hsc| dgl| tie| asa| hyp| mxx| mqr| goc| hym| mjf| jke| wpi| cpe| kgw| zic| tak| oqp| cvc| nxl| hay| rhe| bvn| sif| aas| oer| par| dmm| yhu| huv| ytp| oum| pyo| dvs| ohm| djd| ick| glr|